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Abstract
Receptor Tyrosine Kinases (RTKs) are an important class of receptors involved 
in regulating different cellular functions. The usual pathway of RTK activation 
involves specific ligand binding, dimerization and trans-autophosphorylation. 
Recently, RTK has been extensively studied as they have potential applications in 
targeted cancer therapy. RTK-based therapeutic strategies are promising because 
dysfunction of RTK is connected to a variety of diseases. More specifically, RTK 
has been widely associated with different types of cancer and related diseases. The 
chapter aims to cover recent advances and challenges in RTK related research, to get 
an overview of the problems and possibilities associated with targeted therapy. This 
will help in deciphering novel therapeutic applications in the future.
Keywords: receptor tyrosine kinase, RTK mutations, cancer, targeted therapy,  
RTK inhibitors
1. Introduction
A cell is dependent on a wide array of molecules to perform all its activities in 
a regulated manner. Any disruption in any of the molecules or related pathways 
can lead to various developmental issues and diseases. Hence, a cell depends on 
stringent signaling pathways which enables it to grow, proliferate, differentiate, and 
carry out all physiological processes required for survival and/or apoptosis. One 
such signaling pathway is the Receptor Tyrosine Kinase (RTK) signaling pathway 
which is extremely crucial in almost all kind of cells. This pathway usually begins 
by activation of receptors on the cell membrane, which in turn, undergoes self-
phosphorylation and activation of other downstream signaling targets (Figure 1). 
There are various mechanisms by which RTK can elicit its effects on the cell. Any 
mutation in RTK or its associated targets can be detrimental to the cell, leading to 
various diseases, including cancer. Thus, identifying these mutations and strategiz-
ing therapies targeting such receptors and their associated molecules, can prove to 
pave the path for creating effective anticancer drugs. Tyrosine kinase inhibitors can 
also be used to attenuate the increased activity of RTK signaling pathway. A mul-
titude of cancers have been linked to dysregulation of RTK signaling. This chapter 
covers the current scenario of RTK-associated cancers and the recent therapeutic 
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strategies, either implemented or having the capacity to be implemented in the 
future. An understanding of the recent advances in this field has ample potential to 
investigate the plethora of possibilities ahead.
2.  RTK: at the crossroads of cell growth, proliferation and 
differentiation
Receptor Tyrosine Kinases are a class of very important receptors involved in 
signaling mechanisms related to cell growth, proliferation, survival and develop-
ment. Dysregulation of this receptor or its associated molecules has been linked 
to various diseases, including cancer. Human genome contains around 55 receptor 
tyrosine kinases (RTK). These RTKs undergo several types of post-translational 
modifications, some of which include tyrosine phosphorylation, ubiquitination, 
ectodomain shedding, and regulated intramembrane proteolysis. Structurally RTKs 
are single-pass membrane proteins that are grouped into subfamilies based on simi-
larity in their extracellular domains. The intracellular kinase domains are in turn, 
coupled to different extracellular modules. Many RTKs have been reported to be 
cleaved by gamma-secretase-mediated intramembrane proteolysis. It is a two-step 
process. In the first step, the RTK ectodomain is released to the extracellular space 
by proteolytic cleavage called shedding. In the second step, RTK transmembrane 
domain is cleaved by the gamma-secretase complex. This, in turn, leads to release of 
a soluble RTK intracellular domain that can translocate to various cellular compart-
ments, such as the nucleus or proteasome, and can also interact with transcriptional 
regulators and other molecules to induce cell survival, proliferation and differentia-
tion. The tyrosine kinase domain is an integral part of this intracellular domain [1]. 
The internalization process retains the RTK’s transmembrane domain. The endo-
somal RTK remains active before being recycled or degraded. The transport of RTK 
from endosome-Golgi-ER to the nucleus is primarily dependent on membranous 
vesicles and hence, relies on its interaction with the transport complexes like COP-I 
vesicle complex, Sec61 translocon complex and importin. Nuclear- RTKs have the 
property of retaining oncogenic properties and can enhance cancer progression. 
Nuclear-localized RTKs have, in fact, positive correlation with cancer recurrence 
and therapeutic resistance of cancer patients [2]. It has also been observed that 
reduced ectodomain shedding and decreased ubiquitination of the cytoplasmic 
region produce malignant cells. Events like receptor phosphorylation and ubiquiti-
nation are reversible, whereas proteolytic cleavage events are irreversible. Any such 
modification has the potential to alter the subcellular localization of RTKs [3].
Figure 1. 
Mechanism of activation of the tyrosine kinase receptor. Receptor tyrosine kinase exists as monomers in the 
inactive state. It has an extracellular domain and a cytosolic domain. Upon binding to a specific ligand, it is 
activated by trans-autophosphorylation of the tyrosine kinase domain. This leads to recruitment of specific 
adaptor protein(s) and activation of downstream signaling pathways.
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The activation of RTK is by dimerization of two monomers and this can either 
be receptor-mediated or ligand-mediated. The ligands can either be soluble or 
membrane-embedded. Sometimes, multiple ligands can interact with the same 
receptor. Such ligands often act as biased agonists and can initiate signaling 
responses via activation of the same receptor [4]. Activation of RTK involves 
homodimerization followed by trans autophosphorylation. However, some groups 
of RTKs can interact with each other even in the absence of ligand, which eventually 
leads to heterodimerization across sub-families. This results in irreproducibility of 
data from different experimental sets and hence, is a big hurdle for RTK inhibitors 
to produce desired therapeutic effects [5]. Both genetic and epigenetic modifica-
tions in the genes encoding for RTKs are responsible for activation of growth 
factor-mediated signaling events. This hyperactivation of RTK mediated signaling 
cascades can even cause cancer [6].
The degree and duration of RTK signaling plays a pivotal role in determining 
specific cellular behaviors. The feedback regulation of RTK signaling is critical for 
determining different diseases. The loss of such feedback mechanism can lead to an 
aberrant increase in the RTK signaling, resulting in an uncontrolled increase in cell 
growth, proliferation and survival. Thus, both positive and negative regulators of 
RTK signaling are crucial in development [7].
The use of Tyrosine Kinase Inhibitors (TKI) remains one of the standard 
methods of elucidating anticancer effects. The antitumoral properties of TKIs due 
to induction of apoptosis and cell cycle arrest is a result of tightly controlled events 
involving different cellular compartments such as endoplasmic reticulum and 
mitochondria [8].
3. RTK mutations: targets for cancer therapy
Receptor Tyrosine Kinase and its downstream signaling mechanism is crucial 
for maintaining the integrity of cellular processes, such as growth, proliferation 
and survival. Any mutation in the RTK or its associated partners can be detrimental 
to the cell and can even be oncogenic in nature. A mutation which can directly or 
indirectly lead to upregulation of RTK can eventually result in tumor formation. 
Recent large-scale genomic studies have highlighted the presence of mutations and 
alterations in the genes encoding RTKs such as EGFR, HER2/ErbB2, and MET and 
many other genes. Abnormal RTK activation in human cancers can occur by four 
major pathways: gain-of-function mutations, genomic amplification, chromosomal 
rearrangements, and/or autocrine activation [9].
For instance, loss or inactivation of phosphate and tensin homolog (PTEN), 
leads to overactivation of RTK/PI3K/Akt signaling pathway, eventually leading 
to tumorigenesis. It has been observed that transcription of PTEN pseudogene, 
PTENP1, results in sense and antisense transcripts which can, in turn, exhibit 
post-transcriptional and transcriptional modulation of PTEN expression, respec-
tively. Thus, the effects of the sense and antisense transcripts of PTENP1 on PTEN 
expression can influence RTK expression and associated signaling pathway, and has 
promising potential in cancer therapeutics [10]. Another well studied mutant of 
RTK is MET, which was discovered way back in 1984. The MET RTK and its ligand 
HGF are key players in more than one type of cancer. High expression of the MET 
receptor has been shown to correlate with poor prognosis and resistance to therapy. 
MET exon 14 splicing variants that was initially identified in lung cancer can be 
treated through various tyrosine kinase inhibitors (TKIs) [11].
Additionally, alternative splicing of RTK pre-mRNA is a novel aspect of study, 
which can be linked to development of tumor and its maintenance. However, the 
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exact biological functions of different RTK splice variants and the signals respon-
sible for it is not yet well studied. The mechanism by which these splicing events 
affect the response of tumor to RTK targeted therapies, and whether these therapies 
have any effect on the fate of RTK alternative splicing, is a very interesting aspect 
that can be studied. Moreover, the upstream signals that control their expression in 
tumors, remain to be understood. More importantly, it remains to be determined 
whether, and how, these splicing events may affect the response of tumor cells to 
RTK-targeted therapies, and inversely, whether these therapies may impact these 
splicing events [12].
An overall understanding of the different mutations and alterations related to 
RTK, will provide a deeper understanding of the receptor and pathways that have 
important implications in anticancer therapies. Numerous RTK-targeted therapies 
have been developed to counteract this hyperactivation.
4. RTK disruption in different types of cancer
Receptor Tyrosine kinases are a class of extremely important receptors, and 
hence, any issue with its regulation or expression can bring about changes in a cell’s 
growth, survival, differentiation and metabolism. One of the most significant 
effects of RTK dysregulation is cancer and related phenotypes. RTKs serve as 
important biomarkers that can help analyze tumor progression and metastasis and 
determine diagnosis and prognosis in the patients. Different cancers have been 
observed to have a major link with RTKs. For instance, the Epidermal Growth 
Factor receptor (EGFR) gene has a tyrosine kinase domain, and somatic mutations 
within this domain, has been linked to non-small cell lung cancer (NSCLC) pro-
gression and are called “EGFR sensitizing mutations”. One of its inhibitors, called 
Raf Kinase Inhibitor Protein (RKIP) has the potential to modulate RTK associated 
signaling events, such as those controlled by EGFR. It has been reported to have 
metastasis suppressor role in lung cancer [13].
RTK has also been studied extensively in a complex and heterogenous tumor 
arising from neural crest derived peripheral neurons, known as neuroblas-
toma, which sadly accounts for 10–15% of all childhood related cancer deaths. 
Neuroblastoma tumorigenesis involves a receptor tyrosine kinase known as 
Anaplastic Lymphoma Kinase (ALK), which is a fusion partner in translocation 
events related to different types of cancers. RTK translocations are responsible for 
creating a fusion protein containing a dimerizing partner fused to an RTK kinase 
domain. This, in turn, leads to constitutive kinase domain activation and results in 
altered RTK cellular localization as well as upregulation of different downstream 
signaling. In neuroblastoma, however, the full length ALK RTK is itself mutated 
[14]. Fortunately, many different RTK inhibitors, that are known to inhibit 
ALK, have been FDA approved and can be used in ALK-driven neuroblastoma 
treatment.
Apart from neuroblastoma, another type of cancer-related to the brain is glio-
mas, representing the most common form of malignant brain tumor. Unregulated 
RTKs such as MET and EGFR, have a central role in the progression of glio-
blastoma. Mutations in MET and its various regulatory molecules have been 
linked to different stages of glioblastoma. MET along with its ligand Hepatocyte 
Growth Factor (HGF) have been shown to hold importance in proliferation, 
invasion, migration, angiogenesis, recurrence and therapeutic resistance. 
Targeting HGF/MET in glioma patients is an important therapeutic strategy 
[15]. HGF/MET has also been extensively studied and found to be involved in 
different primary malignant brain tumors such as astrocytomas, glioblastomas, 
5
Recent Advances in the Therapeutic Development of Receptor Tyrosine Kinases (RTK)…
DOI: http://dx.doi.org/10.5772/intechopen.98497
oligodendrogliomas, ependymomas, and embryonal central nervous system 
tumors (including medulloblastomas and others) [16].
Another report highlights the relevance of different types of RTKs such as 
epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor 
(PDGFR), c-Met, Tie, Axl, discoidin domain receptor 1 (DDR1), and erythropoie-
tin-producing human hepatocellular carcinoma (Eph) in glioma invasion, and how 
these can act as targets for glioma therapy [17].
Another common RTK that has been observed in different tumor promoting 
activities, such as cell proliferation and invasion is AXL. It does so by promoting 
EMT events, metastasis and drug-resistance. It can also modulate tumor microenvi-
ronment and corresponding immune response. This RTK is known to be involved in 
cancer progression of different types of malignancies ranging from hematopoietic 
cancers to solid tumors. AXL upregulation has been observed in a wide variety 
of cancer types, such as breast cancer, and is under focus to investigate possible 
therapeutic implications by its modulation [18]. Downstream signaling pathways of 
RTKs such as MAPK, PI3K/Akt and JAK/STAT pathways are major players that regu-
late cancer progression and metastasis, if not regulated [19]. Problems related to 
proper regulation of RTK signaling pathway has also been noted in Acute Myeloid 
Leukemia (AML) [20].
Another type of cancer where issues related to RTK signaling are noted, is osteo-
sarcoma. Multi-target tyrosine kinase inhibitors have shown promising effects in 
the treatment of osteosarcoma, but the exact target is unclear. This is because inhib-
iting any one type of RTK as a target for treatment of osteosarcoma has not been 
proven to be effective. Rather, inhibition of multiple RTKs simultaneously show a 
much better progress in TKI dependent osteosarcoma treatment. This is because 
receptor tyrosine kinases like MET, IGF-1R, AXL, PDGFRs, KIT, and FGFRs might 
be relevant but unimportant targets for osteosarcoma treatment [21].
Gastrointestinal stromal tumor (GIST) is also a type of tumor originating from 
interstitial cells of Cajal in the GI tract, in which genes encoding RTK are mutated. 
Genes such as KIT and PDGFRA are activated and eventually lead to tumor forma-
tion. It has also been noted that RTK inhibitors like imatinib, can significantly act 
as therapeutic agent in treatment of patients with GIST [22]. Inhibition of down-
stream signaling like PI3K/AKT/mTOR also exhibit promising outcomes.
RTK dysregulation has also been observed in head and neck cancers, having 
important implications in tumorigenesis and metastasis. A recent report illustrates 
the association of non-coding RNAs with RTK and confirms that RTKs and RTK 
based therapy are superior to other existing therapeutic interventions for HNC [23].
Although issues in RTK regulation are more common in solid tumors, RTK 
translocations are also observed in hematological malignancies. Fibroblast Growth 
Factor Receptor (FGFR), Platelet-Derived Growth Factor Receptor (PDGFR), 
Rearranged during Transfection (RET), Colony Stimulating Factor 1 Receptor 
(CSF1R), and Neurotrophic Tyrosine Kinase Receptor Type 3 (NTRK3) fusions are 
some of the common anomalies found in hematopoietic disorders [24].
5. An overview of RTK inhibitors
There have been a wide variety of Receptor Tyrosine Kinase (RTK) inhibitors, 
many of which have been approved by the FDA. These inhibitors play a signifi-
cant role in inhibiting the effect of RTK in cells where they are dysregulated, and 
thereby, providing a strategy to inhibit cell growth and proliferation. As a result, 
these inhibitors are well known anticancer agents as well (Figure 2). One such 
example is the inhibitor known as Entrectinib (A) (Figure 2), which shows massive 
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potential in the treatment of very complex childhood cancer, neuroblastoma. This 
type of cancer is mainly caused by differential expression of ALK or TRKA/B/C. 
Entrectinib (RXDX-101) is a pan-ALK, TRKA, TRKB, TRKC, and ROS1 inhibi-
tor with activity against tumors with ALK, NTRK1, NTRK2, NTRK3, and ROS1 
alterations in Phase I clinical trials in adults [25]. In June 2019, Entrectinib got its 
first global approval in Japan, for treating adult and pediatric patients with NTRK 
fusion-positive and advanced or recurrent solid tumors. It is under regulatory 
review for the treatment of adult patients with ROS1-positive non-small cell lung 
cancer (NSCLC). Entrectinib is also under regulatory review in the USA (PDUFA 
date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-
positive solid tumors and ROS1-positive NSCLC [26]. Another example of an 
inhibitor which acts against multiple receptor tyrosine kinases is Cabozantinib  
(B) (Figure 2). This is commercially available as Cabometyx tablet and is used in 
the treatment of hepatocellular carcinoma (HCC). This inhibitor is usually used in 
the treatment of patients who are in an advanced stage of cancer and have already 
been under treatment with the multi-RTK inhibitor sorafenib [27].
6. Promising therapeutic strategies
Receptor Tyrosine Kinases are important regulators of the cell cycle pathway. 
For a cell to grow and proliferate normally, this receptor plays a major role. Hence, 
any form of over-expression or overactivity of the RTK or its associated signaling 
pathway, naturally leads to tumor formation and is well connected with the devel-
opment of cancer. As a result, RTK and its associated pathways have always been 
under investigation to find targets in the fight against cancer.
A recent report establishes the relationship between RTK signaling and DNA 
repair, hinting towards a connection between RTK and the factors involved in the 
repair pathway. Thus, RTKs can act as potential modulators of the DNA repair 
pathway and novel therapeutic strategies can be implemented, which will target 
both DNA repair pathways and RTK mediated signaling pathways [28]. Another 
report also highlights the link between RTK signaling and DNA repair. Activation of 
the serine/threonine kinase AKT, also known as protein kinase B (PKB) stimulates 
DNA repair, like double strand break repair after radiotherapy. Thus, AKT could 
possibly be a major predictive marker of conventional cancer therapy, molecularly 
targeted therapy, and immunotherapy for solid tumors. Activated AKT mediates 
resistance to cancer treatment modalities, such as radiotherapy, chemotherapy, and 
RTK targeted therapy [29]. Checkpoint inhibitors such as pembrolizumab have 
proven effective at extending survival for mismatch repair (MMR)-deficient and 
high microsatellite instability (MSI) metastatic colorectal patients.
Figure 2. 
Structure of potent RTK inhibitors. (A) Entrectinib (B) Cabozantinib.
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Different RTK mutations, deletions, translocations and amplification/over-
expressions have been identified and these are currently under study to elucidate 
their role in cancer. The therapeutic strategies involving RTKs can be classified into 
small molecule inhibitors and monoclonal antibodies [30].
The presence of RTK fusions is by large, responsible for providing acquired 
resistance to different therapies. This poses a challenge in the administration of 
Tyrosine Kinase Inhibitors as anticancer treatment and thus, is a field that requires 
a lot of attention. Recent reports have come up with the different strategies that can 
be beneficial in solving this issue [31].
Another interesting and emerging study reveals the connection between 
EGFR, a common RTK that is dysregulated in different malignancies, and autoph-
agy. In fact, autophagy upregulation as well as downregulation has been observed 
in several cancers, highlighting its oncogenic and tumor suppressor properties 
in tumor progression. EGFR has the potential to determine whether autophagy 
will have a cytotoxic or cytoprotective effect. The EGFR-mediated pathways or 
proteins involved in autophagy regulation include (a) the EGFR-mTOR pathway; 
(b) the EGFR-RAS pathway; (c) EGFR-Beclin1; [8] the EGFR-STAT3 pathway and 
(e) EGFR-LAPTM4B (oncoprotein lysosomal-associated transmembrane protein 
4B). Thus, understanding the regulation of autophagy by EGFR can prove to be 
a highly efficient strategy to identify potential cancer therapeutic targets [32]. 
Anti-epidermal growth factor receptor (anti-EGFR) agents panitumumab and 
cetuximab, combined with chemotherapy, have also prolonged the survival of 
cancer patients.
One of the most promising therapeutic strategy which is widely established and 
used is immunotherapy. It has proved its worth by improving the prognosis of many 
patients with a broad variety of hematological and solid malignancies. The impor-
tance of immunotherapy has been acknowledged by the Nobel prize for physiology or 
medicine 2018 awarded for the discovery of cytotoxic T-lymphocyte-associated pro-
tein (CTLA-4) to James P. Allison and programmed cell death protein 1/programmed 
cell death protein ligand 1 (PD-1/PD-L1) to Tasuku Honjo [33].
Epithelial-mesenchymal transition (EMT) is a very important event in the 
prognosis of malignancy. It has been studied that a receptor tyrosine kinase AXL 
can directly affect the mesenchymal state, making the tumor more aggressive and 
drug-resistant. The inhibition of AXL has come up as a promising therapeutic 
strategy in reversing EMT resensitization to other tyrosine kinase inhibitors, 
mitotic inhibitors, and platinum-based therapy. Therefore, novel ways to inhibit 
AXL can be used as an effective therapeutic strategy against different types of can-
cer [34]. AXL receptor tyrosine kinase (RTK) and its ligand, growth arrest-specific 
protein 6 (Gas6), have been known to be involved in different malignancies and 
autoimmune disorders. Several molecules are presently under investigation, which 
can aid in targeting the AXL/Gas6 molecular system, thus providing therapeutic 
and diagnostic applications [35].
Apart from the inhibitors that directly target the RTK and its associated 
molecules, some molecules are naturally present with antitumor properties. One 
such molecule is decorin, which is present in the tumor microenvironment. This 
molecule is prototype member of the SLRP family found in a variety of tissues and 
is expressed in the stroma of various forms of cancer. Decorin has recently gained 
a lot of attention because of its effects in inflammation, fibrotic disorders, and 
cancer. Since it is present in the tumor microenvironment, it has been proposed 
to act as a “guardian from the matrix.” Soluble decorin has a pan-RTK inhibiting 
property and can target a few RTKs, including EGFR, Met, IGF-IR, VEGFR2, and 
PDGFR. Decorin/RTK interaction can induce caveosomal internalization and 
receptor degradation. Additionally, this interaction can trigger cell cycle arrest 
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and lead to apoptosis, and can induce conserved catabolic processes, such as 
endothelial cell autophagy and tumor cell mitophagy. Antimetastatic and antian-
giogenic processes have also been reported to be induced by decorin/RTK interac-
tion. Due to such diverse plethora of anticancer effects, decorin is a promising 
candidate for combatting cancer, especially the cancer types where the major issue 
is with RTK signaling [36].
Combinations of immunotherapies, RTKs, monoclonal antibodies, and cyto-
toxic drugs are being investigated to provide broad-spectrum protection against 
relapse by simultaneously targeting many cancer hallmarks [37].
7. Challenges in RTK related research
Despite the huge potential and success of RTK based targeted cancer therapy, 
there remain some challenges in this field. One of the major challenges is reducing 
the off-target effects of Tyrosine Kinase Inhibitors. This non-specificity can lead 
to deleterious effects on normal cells as well. A possible solution to this challenge 
can be TKIs-based nanodelivery systems, that will specifically target tumor cells 
[38]. Another common challenge faced by any anticancer drug is the induction 
of chemo-resistance during therapy. Patients may invariably develop resistance 
to these therapies, leading to recurrence. Research that will aim in dealing with 
chemoresistance by manipulating specific molecules related to it, can have poten-
tial role in overcoming this challenge [39]. Thus, increasing target specificity and 
decreasing drug resistance are the major challenges in RTK related research, along 
with identification of novel TKIs.
8. Conclusion
This chapter covers the recent advances made in the field of signaling biology, 
mainly Receptor Tyrosine Kinase-mediated signaling. The structural and functional 
aspects of the receptor, modes of its activation and current research-based on it has 
been discussed. Additionally, information related to RTK mutations and disruptions 
in different types of cancers, gives a better understanding of the different anti-
cancer therapeutic strategies that have come up in the form of inhibitor molecules 
and drugs. The scope of these receptors is huge if they can be exploited further, 
along with identification of other novel mutations associated with cancer, and their 
targets. Sequencing data based on different types of cancer cells, including hema-
tological and solid tumors, can provide a clear picture of the RTK associated genes 
that are either upregulated or downregulated in different diseases. These studies 
will open new avenues because different inhibitors/activators or drugs that can 
target such RTK or its associated molecules, can either be extracted from natural 
sources or designed in the laboratories. This, in turn, has the potential of targeted 
therapies and may prove beneficial in the treatment of different types of diseases 
including cancer.
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